Last reviewed · How we verify

NCT04054271

Effects of ABO Blood Types on the Survival and Marginal Bone Resorption of Dental Implants

Completed Last updated 13 August 2019
What this trial tests

trial in Implant Tissue Failure in 963 participants. Completed in 15 December 2018.

Timeline
15 December 2017
Primary endpoint
15 December 2018
15 December 2018

Quick facts

Lead sponsorYuzuncu Yil University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment963
Start date15 December 2017
Primary completion15 December 2018
Estimated completion15 December 2018
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Yuzuncu Yil University

Who can join

Adults 19 to 78, any sex, with Implant Tissue Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates implant survival and marginal bone resorption in patients receiving implant treatment with respect to demographic data and AB0 (groups) blood types.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Yuzuncu Yil University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04054271.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing